Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02865811 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT02865811 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 26 participants.
The verdict
NCT02865811, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This research study is studying the combination of Pegylated Liposomal Doxorubicin (PLD) and Pembrolizumab as a possible treatment for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer that is resistant to platinum therapy. The following interventions will be used in this study: * Pegylated liposomal doxorubicin (PLD) * Pembrolizumab
Interventions
- DRUG Pembrolizumab
- DRUG Pegylated Liposomal Doxorubicin (PLD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-09-15 |
| Est. Completion | 2022-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02865811
The ClinicalTrials.gov registry entry for NCT02865811 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02865811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02865811 about?
NCT02865811 is a clinical study titled "Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer". This research study is studying the combination of Pegylated Liposomal Doxorubicin (PLD) and Pembrolizumab as a possible treatment for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer that is resistant to platinum therapy. The following interventions will be used in this study: * Pegylated l...
What is the current status of trial NCT02865811?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2016-09-15. Estimated completion is 2022-03.
What interventions are being tested in trial NCT02865811?
The interventions under investigation include: Pembrolizumab (DRUG), Pegylated Liposomal Doxorubicin (PLD) (DRUG).
Who is sponsoring clinical trial NCT02865811?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.